Kura Oncology (NASDAQ:KURA) Shares Up 5.5% - What's Next?

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report)'s stock price traded up 5.5% during trading on Monday . The stock traded as high as $6.19 and last traded at $6.23. 79,864 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 1,515,990 shares. The stock had previously closed at $5.90.

Analyst Ratings Changes

Several research firms recently issued reports on KURA. JMP Securities reiterated a "market outperform" rating and set a $28.00 price target on shares of Kura Oncology in a research report on Thursday, February 6th. Wedbush reiterated an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Tuesday, April 8th. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. UBS Group decreased their target price on Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Finally, StockNews.com raised shares of Kura Oncology from a "hold" rating to a "buy" rating in a report on Friday, April 4th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $25.50.

Kura Oncology Stock Up 6.1 %

The stock's 50-day moving average price is $7.07 and its 200-day moving average price is $10.34. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market cap of $505.67 million, a price-to-earnings ratio of -2.65 and a beta of 0.83.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. On average, sell-side analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares of the company's stock, valued at $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds have recently bought and sold shares of the company. Jane Street Group LLC lifted its position in shares of Kura Oncology by 36.7% during the 3rd quarter. Jane Street Group LLC now owns 126,085 shares of the company's stock worth $2,464,000 after buying an additional 33,848 shares in the last quarter. Barclays PLC boosted its position in Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company's stock worth $3,234,000 after purchasing an additional 84,563 shares during the last quarter. Geode Capital Management LLC grew its stake in Kura Oncology by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock valued at $34,798,000 after purchasing an additional 41,535 shares during the period. Franklin Resources Inc. increased its position in shares of Kura Oncology by 1.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock valued at $28,687,000 after purchasing an additional 23,113 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Kura Oncology by 0.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company's stock worth $7,997,000 after buying an additional 3,092 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.